Controlled drug release

Slides:



Advertisements
Similar presentations
Instant Clinical Pharmacology E.J. Begg
Advertisements

First, zero, pseudo-zero order elimination Clearance
III. Drug Metabolism  The aim of drug metabolism is to convert lipid soluble (non polar) drugs to polar metabolites easily excreted in urine.  The liver.
PHT 415 BASIC PHARMACOKINETICS Course Instructor:Prf. Dr. Hnaa elsaghir Assistant lecturers, Doaa elshora and eman elfakih Text: Hand book of basic pharmacokinetics,
Introduction to Pharmacology. Overview Pharmaceutics Pharmacokinetics Pharmacodynamics.
Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.
Pharmacokinetics of Drug Absorption
Pharmacokinetics & Pharmacodynamics of Controlled Release Systems Presented By: Govardhan.P Dept. of pharmaceutics, University College of Pharmaceutical.
 Modified drug release dosage forms:  These dosage forms are designed to release drugs in a controlled manner, at a predetermined rate, duration and.
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 25 Drug Interactions.
Laplace transformation
Practical Pharmacokinetics
Dose Adjustment in Renal and Hepatic Disease
Gokaraju Rangaraju College of Pharmacy
Clinical Pharmacokinetics. Clinical Pharmacodynamics. Drugs’ Interaction. Adverse Effects of Drugs.
Week 6- Bioavailability and Bioequivalence
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
Lecture 2.  Clearance Ability to eliminate the drug  Volume of distribution (Vd) The measure of the apparent space in the body available to contain.
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 3 Therapeutic Range.
Bioavailability Dr Mohammad Issa.
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
Multiple Dosing: Intermittent or multiple dose regimen
Pharmacokinetics of strong opioids Susan Addie Specialist palliative care pharmacist.
1 Controlled drug release Dr Mohammad Issa. 2 Frequency of dosing and therapeutic index  Therapeutic index (TI) is described as the ratio of the maximum.
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas.
The General Concepts of Pharmacokinetics and Pharmacodynamics
Multiple dosing: intravenous bolus administration
1 Single-dose kinetics Plasma [Drug] curve Upon administration [drug] plasma reaches a max Then begins to decline as the Drug is eliminated Cp max = max.
Calculation of Doses Prof. Dr. Henny Lucida, Apt.
Continuous intravenous infusion (one-compartment model)
INTRODUCTION CLINICAL PHARMACOKINETICS
BIOPHARMACEUTICS.
1 Pharmacokinetics: Introduction Dr Mohammad Issa.
TDM Therapeutic Drug Monitoring
© Paradigm Publishing, Inc.1 Chapter 2 Basic Concepts of Pharmacology.
Prof. Dr. Henny Lucida, Apt
Modified release products. Considerations in the evaluation of modified release products Requirements for preparing extended release products. The bioavailability.
Design of Sustained Release Dosage Forms
PHT 415 BASIC PHARMACOKINETICS
415 PHT Plasma Level – Time Curve
DOSAGE ADJUSTMENT IN RENAL AND HEPATIC DISEASES Course Title : Biopharmaceutics and Pharmacokinetics – II Course Teacher : Zara Sheikh.
Basic Concepts of Pharmacology © Paradigm Publishing, Inc.
CHAPTER 3. Pharmacokinetics: the study of how a drug moves into, through, and out of the body How is it absorbed into the body, where is it distributed.
MULTIPLE DOSAGE REGIMEN
SIVANAGESWARARAO MEKALA ASSISTANT PROFESSOR DEPT OF CLINICAL PHARMACOLOGY.
Drug Response Relationships
routes of drug administration By Hawra alsofi
Pharmacokinetics Tutoring
Presentation On Routes of drug administration & it’s significance
Biopharmaceutics of modified release drug products
Biopharmaceutics factors affecting Modified release products
Pharmacokinetics Tutoring
Applications of Pharmacokinetics
Anticonvulsants: Valproic acid
Pharmacokinetics and Pharmacodynamics
Pharmaceutics 2.
Oral Sustained & Controlled Drug Delivery System
Pharmacology.
Clinical Pharmacokinetics
Firdaus | Sofia | Nurainiza | Hafizah
Pharmacologic Principles – Chapter 2
Pharmacokinetics and Factors of Individual Variation
Drug Delivery Systems Pharmaceutical technology Petra University.
Selected Bioavailability and Pharmacokinetic Calculations
1 Concentration-time curve
Therapeutic Drug Monitoring chapter 1 part 1
Multiple ORAL Dosing Objectives
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Presentation transcript:

Controlled drug release Dr Mohammad Issa

Frequency of dosing and therapeutic index Therapeutic index (TI) is described as the ratio of the maximum drug conc in the blood that can be tolerated to the minimum drug conc needed to produce a satisfactory clinical response. In some cases these ranges are narrow, resulting in small therapeutic index We seek to maintain drug conc in blood within the Therapeutic range during therapy. This requires not only the selection of an appropriate daily dose, the drug must also be given with sufficient frequency so as to minimize the range of blood conc that are produced. The ratio of max to minimum drug conc at steady state should not exceed the therapeutic index of the drug.

Frequency of dosing and therapeutic index For drugs that are absorbed and distributed rapidly, the following relation apply

Frequency of dosing and therapeutic index A drug with the TI of 2, t1/2 of 3 hrs must be given no less frequently than every 3 hours A drug with similar half life but a therapeutic index of 4 may be given every 6 hours

Absorption rate and frequency of dosing Dosing regimen for rapidly absorbed drugs are a function of the pharmacodynamics and pharmacokinetics of the drug molecule, they must be based on the therapeutic index and half life of the drug Reducing the absorption rate of a drug by controlling the rate of drug release in the dosage form, can dramatically affect drug conc at steady state For a given formula, the slower the release of the drug, the smaller is the ratio of maximum to minimum drug con at steady state. Under these conditions, we can give larger doses at less frequent intervals and still stay within the therapeutic conc of the drug

Absorption rate and frequency of dosing Prolonged release medication offer obvious advantages for drugs with short half lives and narrow therapeutic indices. As they permit the drug to be given at more reasonable intervals within the day (improve patient compliance) They also minimize the peak to trough drug conc ratio, which may be useful for many drugs. For example: potassium depleting hydrocholrthiazides: their potassium depleting effect disappears when the fluctuations in blood levels decrease. Nephrotoxicity of gentamicin is reduced when steady state conc are reached and maintained in a narrow range.

Zero order release Continuous, constant rate IV infusion leads to constant blood levels. Under these conditions blood levels are invariant with time, there are no peaks and troughs Provided that the constant drug conc is within the therapeutic range, this is an ideal situation for many drugs The only way to achieve constant blood levels is to administer the drug at a constant (zero-order) rate over the entire dosing interval.

Zero order release Fluctuations in blood levels do occur as a result of transient changes in clearance or in the delivery rate, but they are usually small Constant rate release is not limited to infusion, today there are dosage forms oral, ocular, intravaginal, IM that release the drug in a zero order or near zero order fashion.

Oral prolonged release medications Most prolonged release medications are intended for oral use. A prolonged release unit usually contains more drug than a conventional dosage unit, but it intended to be given less frequently A drug that is usually administered at a dose of 250 mg 4 times daily, may be given at a dose of 500 mg twice daily, or 1 gm once daily

Oral prolonged release medications The ultimate criteria of for evaluating such dosage forms are: the amount of drug intended to be absorbed is indeed absorbed in a predictable and consistent manner the steady state ratio of maximum to minimum drug conc is no greater or optimally less than that produced by the more frequently administered conventional dosage forms

Potential advantages oral prolonged release medications Improved control of the maintenance therapuetic level of the drug which permit: improved treatment of many chronic illnesses where symptoms breakthrough occurs if plasma levels went down (asthma, depression) maintenance of the therapeutic action during night (management of pain) reduction in the incidence and severity of side effects caused by increased plasma levels improved patient compliance reduction of the incidence and severity of gastrointestinal side effects caused by irritant drugs administered in a conventional dosage form

Potential limitations oral prolonged release medications variable physiological factors (gastric emptying, gastric and intestinal transit rate, food) which often influence drug bioavailability of conventional dosage form may also interfere with the precision of control of release of the SR dosage forms the rate of transit of the sustained release oral dosage form along the GI limits the maximum period of time for which the therapeutic response is maintained Sustained release dosage forms which tend to remain intact, may become lodged at some sit of the GI--- slow release, high localized conc of drug, local irritation

Potential limitations oral prolonged release medications Reduced potential for accurate dosage adjustment: fine dose adjustment is difficult. Dose dumping: uncontrolled rapid release of the drug material due to failure of the formulation which result in abnormal high blood levels of circulating drug